Imaging polyglutamine deposits in brain tissue.

The formation of polyglutamine aggregates occupies a central role in the pathophysiology of neurodegenerative diseases caused by expanded trinucleotide repeats encoding the amino acid glutamine. This chapter describes sensitive histological methods for detection of tissue sites that are capable of further recruitment of polyglutamine and for sites rich in polyglutamine defined immunohistochemically. These methods have been found to be applicable in a number of diseases and animal models of disease. Recruitment, which is a property of highly ordered, amyloid-like aggregates, is most commonly found in punctate sites, termed aggregation foci (AF), in the neuronal perikaryonal cytoplasm. As expected, these AF correspond to sites containing polyglutamine aggregates detected using the antibody 1C2. Interestingly, however, many of the latter sites, including most neuropil aggregates and neuronal intranuclear inclusions, exhibit a limited ability to support polyglutamine recruitment. Thus there is limited correlation between the distribution of polyglutamine aggregates and recruitment activity, suggesting functional heterogeneity among polyglutamine aggregates. These methods should prove useful in explaining the relationship between aggregation reactions, aggregate formation, and the development of symptomatic disease and should be adaptable to the study of other protein aggregation disorders.

[1]  Peter S. Harper,et al.  Huntington's disease , 1991 .

[2]  Hans Lehrach,et al.  Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro and In Vivo , 1997, Cell.

[3]  R. Wetzel,et al.  A microtiter plate assay for polyglutamine aggregate extension. , 2001, Analytical biochemistry.

[4]  Joe C. Adams,et al.  Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[5]  E. Simpson,et al.  Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. , 2003, Human molecular genetics.

[6]  D. Moras,et al.  Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[7]  G. Hoffman,et al.  cFos immunoreactivity is enhanced with biotin amplification. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[8]  Claire-Anne Gutekunst,et al.  Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology , 1999, The Journal of Neuroscience.

[9]  Kenneth H. Johnson,et al.  Staining methods for identification of amyloid in tissue. , 1999, Methods in enzymology.

[10]  K. Fischbeck,et al.  Intranuclear Inclusions of Expanded Polyglutamine Protein in Spinocerebellar Ataxia Type 3 , 1997, Neuron.

[11]  G P Bates,et al.  Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Mantyh,et al.  Deposition of soluble amyloid-beta onto amyloid templates: with application for the identification of amyloid fibril extension inhibitors. , 1999, Methods in enzymology.

[13]  R. Wetzel CHAPTER 34 – Chemical and Physical Properties of Polyglutamine Repeat Sequences , 2006 .

[14]  Y. Agid,et al.  Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias , 1995, Nature.

[15]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[16]  M. Chesselet,et al.  Time course of early motor and neuropathological anomalies in a knock‐in mouse model of Huntington's disease with 140 CAG repeats , 2003, The Journal of comparative neurology.

[17]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[18]  C. Ross,et al.  A Mutant Ataxin-3 Putative-Cleavage Fragment in Brains of Machado-Joseph Disease Patients and Transgenic Mice Is Cytotoxic above a Critical Concentration , 2004, The Journal of Neuroscience.

[19]  Carlos Cepeda,et al.  Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect , 2004, Trends in Neurosciences.

[20]  Thomas Walther,et al.  Transgenic rat model of Huntington's disease. , 2003, Human molecular genetics.

[21]  S. Warren,et al.  Genetic instabilities and hereditary neurological diseases , 1998 .

[22]  D. Rosene,et al.  A cryoprotection method that facilitates cutting frozen sections of whole monkey brains for histological and histochemical processing without freezing artifact. , 1986, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[23]  Ronald Wetzel,et al.  Amyloid-like features of polyglutamine aggregates and their assembly kinetics. , 2002, Biochemistry.

[24]  M. MacDonald,et al.  Amyloid Formation by Mutant Huntingtin: Threshold, Progressivity and Recruitment of Normal Polyglutamine Proteins , 1998, Somatic cell and molecular genetics.

[25]  S. W. Davies,et al.  Detection of polyglutamine aggregation in mouse models. , 1999, Methods in enzymology.

[26]  K. Sletten,et al.  Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens. , 2001, American journal of clinical pathology.

[27]  R. Wetzel,et al.  Solubilization and disaggregation of polyglutamine peptides , 2001, Protein science : a publication of the Protein Society.

[28]  J T Finch,et al.  Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.